Danish biotech is on the rise: in 2006, companies raised unprecedented amounts of venture capital, pried open the window for initial public offerings and tempted investorswith follow-up offerings.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Australia and New Zealand Health Policy Open Access 01 June 2007
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moran, N. Danish biotech outperforms its European counterparts. Nat Biotechnol 24, 1460–1461 (2006). https://doi.org/10.1038/nbt1206-1460
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1460
This article is cited by
-
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Australia and New Zealand Health Policy (2007)
